ERK activation via A1542/3 limonoids attenuates erythroleukemia through transcriptional stimulation of cholesterol biosynthesis genes
Open Access
- 9 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 21 (1), 1-12
- https://doi.org/10.1186/s12885-021-08402-6
Abstract
Background: Cholesterol plays vital roles in human physiology; abnormal levels have deleterious pathological consequences. In cancer, elevated or reduced expression of cholesterol biosynthesis is associated with good or poor prognosis, but the underlying mechanisms are largely unknown. The limonoid compounds A1542 and A1543 stimulate ERK/MAPK by direct binding, leading to leukemic cell death and suppression of leukemia in mouse models. In this study, we investigated the downstream consequences of these ERK/MAPK agonists in leukemic cells. Methods: We employed RNAseq analysis combined with Q-RT-PCR, western blot and bioinformatics to identify and confirm genes whose expression was altered by A1542 and A1543 in leukemic cells. ShRNA lentiviruses were used to silence gene expression. Cell culture and an animal model (BALB/c) of erythroleukemia induced by Friend virus were utilized to validate effects of cholesterol on leukemia progression. Results: RNAseq analysis of A1542-treated cells revealed the induction of all 18 genes implicated in cholesterol biosynthesis. Expression of these cholesterol genes was blocked by cedrelone, an ERK inhibitor. The cholesterol inhibitor lovastatin diminished ERK/MAPK activation by A1542, thereby reducing leukemic cell death induced by this ERK1/2 agonist. Growth inhibition by cholesterol was observed both at the intracellular level, and when orally administrated into a leukemic mouse model. Both HDL and LDL also suppressed leukemogenesis, implicating these lipids as important prognostic markers for leukemia progression. Mechanistically, knockdown experiments revealed that the activation of SREBP1/2 by A1542-A1543 was responsible for induction of only a sub-set of cholesterol biosynthesis genes. Induction of other regulatory factors by A1542-A1543 including EGR1, AP1 (FOS + JUN) LDLR, IER2 and others may cooperate with SREBP1/2 to induce cholesterol genes. Indeed, pharmacological inhibition of AP1 significantly inhibited cholesterol gene expression induced by A1542. In addition to leukemia, high expression of cholesterol biosynthesis genes was found to correlate with better prognosis in renal cancer. Conclusions: This study demonstrates that ERK1/2 agonists suppress leukemia and possibly other types of cancer through transcriptional stimulation of cholesterol biosynthesis genes.Funding Information
- National Natural Science Foundation of China (21867009 and U1812403)
- Guizhou Science and Technology Department (QKHPTRC[2019]5627)
This publication has 45 references indexed in Scilit:
- The metabolic landscape of RAS-driven cancers from biology to therapyNature Cancer, 2021
- Berberine Attenuates Cholesterol Accumulation in Macrophage Foam Cells by Suppressing AP-1 Activity and Activation of the Nrf2/HO-1 PathwayJournal of Cardiovascular Pharmacology, 2020
- Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulationThe Journal of Experimental Medicine, 2017
- Regulation of tumour necrosis factor signalling: live or let dieNature Reviews Immunology, 2015
- Statin Use and Reduced Cancer-Related MortalityThe New England Journal of Medicine, 2012
- The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Early Growth Response 1 (Egr1) Regulates Cholesterol Biosynthetic Gene ExpressionOnline Journal of Public Health Informatics, 2011
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensationTrends in Biochemical Sciences, 2011
- Cellular cholesterol trafficking and compartmentalizationNature Reviews Molecular Cell Biology, 2008
- Identification and mapping of a common proviral integration site Fli-1 in erythroleukemia cells induced by Friend murine leukemia virus.Proceedings of the National Academy of Sciences of the United States of America, 1990